Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Carcinoid Syndrome: Results of a Phase 2, Multicenter, Open-label, Serial-Ascending Study Abstract #661
Introduction: Excess serotonin (5-HT) in patients (pts) with carcinoid syndrome (CS) is associated with symptoms including increased bowel movement (BM) frequency.
Aim(s): We evaluated the safety/tolerability of telotristat etiprate in CS with intrapatient dose escalation/2 weeks (150, 250, 350, and 500 mg tid) in pts averaging >4 BM/day, with/without concomitant somatostatin analogs.
Materials and methods: Efficacy objectives included evaluation of change in BM/day, stool form, abdominal pain, flushing, adequate relief (AR) of gastrointestinal symptoms, and urinary 5-hydroxyindoleacetic acid (u5-HIAA) levels. The maximum dose/patient was extended for 4 weeks, (total 12 weeks dosing). If a dose limiting toxicity occurred, the dose was reduced to the prior level.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
Authors: Pavel M, Wiedenmann B, Caplin M, Hörsch D, Freiman J, Law L, Banks P, Frazier K, Jackson J, Lapuerta P, Sands A, Zambrowicz B
To read results and conclusion, please login ...
Further abstracts you may be interested in
#396 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study
Introduction: Excess serotonin (5-HT) may cause gastrointestinal (GI) symptoms (e.g., diarrhea) in carcinoid syndrome (CS) patients. Telotristat etiprate is an oral serotonin synthesis inhibitor designed to reduce peripheral 5-HT levels and alleviate GI distress.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Dr Marianne E Pavel
#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)
Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Research Prof Kimberly Webster
#1811 Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies
Introduction: Two randomized double-blind (DB) trials demonstrated the efficacy of LAN 120mg/4weeks vs placebo in NETs: PFS improved in metastatic non-functioning intestinal/pancreatic NETs (CLARINET); less rescue medication used for carcinoid syndrome (CS) (ELECT).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Alexandria T Phan
#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Dr Larry K Kvols
#849 Patient-Reported Symptom Experiences Following Participation in a Study of Telotristat Etiprate for Patients with Neuroendocrine Tumors and Diarrhea Not Adequately Controlled on Octreotide
Introduction: Telotristat etiprate (LX1606), an oral tryptophan hydroxylase (TPH) inhibitor, was recently evaluated in a dose-escalation (DE) study in patients (pts) with carcinoid tumors and diarrhea not adequately controlled on octreotide.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Dr. Matthew H Kulke